Advice
following a full submission:
tirbanibulin (Klisyri®) is accepted for use within NHSScotland.
Indication under review: field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.
In two phase III studies, a greater proportion of adults with actinic keratosis affecting an area of 25cm2 on the face or scalp achieved complete clearance when treated with tirbanibulin ointment 1% compared with vehicle.
Medicine details
- Medicine name:
- tirbanibulin (Klisyri)
- SMC ID:
- SMC2395
- Indication:
Field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.
- Pharmaceutical company
- Almirall Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 December 2021